Implementation Effectiveness and Safety of Tenofovir Gel Provision Through Family Planning Services

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

372

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

April 30, 2015

Study Completion Date

December 31, 2015

Conditions
HIV
Interventions
DRUG

1% tenofovir gel

"Participants will be randomized to receive 1% tenofovir gel through either:~* Public sector family planning services with 2-3 monthly provision and monitoring of 1% tenofovir gel and the use of QI methodology to promote reliable service delivery (intervention arm), or~* The CAPRISA research clinics with monthly provision and monitoring of 1% tenofovir gel (control arm)."

Trial Locations (2)

4001

CAPRISA eThekwini Clinical Research Site, Durban

Unknown

CAPRISA Vulindlela Clinical Research Site, Pietermaritzburg

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

CONRAD

OTHER

collaborator

Gilead Sciences

INDUSTRY

collaborator

FHI 360

OTHER

collaborator

Institute for Healthcare Improvement

OTHER

lead

Centre for the AIDS Programme of Research in South Africa

NETWORK